copper dotatate Cu-64 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5411 | 1426155-87-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Copper Cu-64 dotatate is a radioactive diagnostic drug. It binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSTR2). It binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress SSTR2 receptors. Copper Cu 64 is a positron (beta+) emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 3, 2020 | FDA | RADIOMEDIX |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V09IX15 | VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS TUMOUR DETECTION Other diagnostic radiopharmaceuticals for tumour detection |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Positron emission tomography | indication | 82918005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 4mL (1mCi/ML) | DETECTNET | RADIOMEDIX | N213227 | Sept. 3, 2020 | RX | SOLUTION | INTRAVENOUS | 10159759 | Aug. 23, 2032 | USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS |
| 4mL (1mCi/ML) | DETECTNET | RADIOMEDIX | N213227 | Sept. 3, 2020 | RX | SOLUTION | INTRAVENOUS | 10383961 | Aug. 23, 2032 | USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS |
| 4mL (1mCi/ML) | DETECTNET | RADIOMEDIX | N213227 | Sept. 3, 2020 | RX | SOLUTION | INTRAVENOUS | 11160888 | Aug. 23, 2032 | USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 4mL (1mCi/ML) | DETECTNET | RADIOMEDIX | N213227 | Sept. 3, 2020 | RX | SOLUTION | INTRAVENOUS | Sept. 3, 2025 | NEW CHEMICAL ENTITY |
| 4mL (1mCi/ML) | DETECTNET | RADIOMEDIX | N213227 | Sept. 3, 2020 | RX | SOLUTION | INTRAVENOUS | Sept. 3, 2027 | FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Somatostatin receptor type 2 | GPCR | BINDING AGENT | Kd | 7.69 | SCIENTIFIC LITERATURE | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D11882 | KEGG_DRUG |
| CHEMBL4297339 | ChEMBL_ID |
| C000718307 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB15873 | DRUGBANK_ID |
| 018491 | NDDF |
| 926371003 | SNOMEDCT_US |
| 926394002 | SNOMEDCT_US |
| C3502191 | UMLSCUI |
| 124220636 | PUBCHEM_CID |
| 2396442 | RXNORM |
| 340817 | MMSL |
| 39013 | MMSL |
| d09680 | MMSL |
| N3858377KC | UNII |
Pharmaceutical products:
None